

Clinical and Genetic Features in Patients with Cystic Fibrosis in Southwestern Iran

Shirin Farjadian^{1,2}, PhD; Mozhgan Moghtaderi¹, MD; Sara Kashefi^{1,3}, MD; Soheila Alyasin^{1,3}, MD;
Khadijehsadat Najib⁴, MD; Forough Saki⁵, MD

1. Allergy Research Center, Shiraz University of Medical Sciences, Shiraz, Iran
2. Department of Immunology, Shiraz University of Medical Sciences, Shiraz, Iran
3. Department of Pediatric Immunology and Allergy, Shiraz University of Medical Sciences, Shiraz, Iran
4. Department of Pediatrics, Shiraz University of Medical Sciences, Shiraz, Iran
5. Department of Pediatric Endocrinology, Shiraz University of Medical Sciences, Shiraz, Iran

Received Oct 23, 2012; Accepted: Dec 16, 2012; First Online Available: Jan 17, 2013

Abstract

Objective: Cystic fibrosis (CF) is a common autosomal recessive genetic disease caused by a mutation in the CF transmembrane conductance regulatory (*CFTR*) gene. This study attempted to identify the most common *CFTR* mutations and any correlations between certain mutations and the clinical presentation of the disease in CF patients in southwestern Iran.

Methods: Twenty nine common *CFTR* gene mutations were examined in 45 CF patients.

Findings: Chronic cough, intestinal obstruction, dehydration, heat exhaustion and steatorrhea were the most common early clinical symptoms among our patients. The most common mutation was $\Delta F508$, with an allele frequency of 21%. The homozygous $\Delta F508$ mutation was observed in eight patients (18%), and three patients (7%) were $\Delta F508$ carriers. The 2183AA>G mutation was observed in four patients, one of whom was also a $\Delta F508$ carrier. The R1162X mutation was detected in two patients. The G542X, R334W and N1303K mutations were detected each in one patient, the first of whom was also a $\Delta F508$ carrier.

Conclusion: Out of 45 patients, 27 (60%) had none of the *CFTR* gene mutations we tested for. The most frequent mutations in southwestern Iranian patients with CF should be identified by sequencing the entire *CFTR* gene in order to optimize the design of a diagnostic kit for common regional mutations.

Iranian Journal of Pediatrics, Volume 23 (Number 2), Apr 2013, Pages: 212-215

Key Words: Cystic Fibrosis; *CFTR* Gene Mutations; Clinical Presentation

Introduction

Cystic fibrosis (CF) is a common autosomal recessive genetic disease caused by mutation in the CF transmembrane conductance regulatory (*CFTR*) gene. Missing or defective *CFTR* gene products in patients with CF lead to multiorgan dysfunctions such as severe lung disease, pancreas dysfunction and elevated sweat chloride^[1]. Cystic fibrosis is less common among African, American and Asian people than among northern Europeans^[2].

To date, 1932 mutations have been reported in the *CFTR* gene worldwide^[3]. The most common *CFTR* gene mutation is $\Delta F508$, which accounts for about 30% to 80% of all mutant alleles worldwide^[1]. The frequency of this mutation is reportedly between 16% and 23% in different parts of Iran^[4-8].

Because the type and distribution of these mutations vary widely among populations^[3], this study attempted to identify the most common *CFTR* gene mutations in patients in southwestern Iran with CF and search for correlations between

* Corresponding Author;

Address: Department of Immunology, Shiraz University of Medical Sciences, Zand St., 71348-45794 Shiraz, Iran

E-mail: farjadsh@sums.ac.ir

© 2013 by Pediatrics Center of Excellence, Children's Medical Center, Tehran University of Medical Sciences, All rights reserved.

certain mutations and the clinical presentation of the disease.

Subjects and Methods

This cross-sectional study was conducted over a period of three years from 2009 to 2012 in southwestern Iran. The diagnosis of CF was based on the typical clinical features of the disease and two abnormal sweat chloride values (>60 mEq/L). Patients with CF were included in this study after written informed consent was obtained from the patients themselves (if ≥ 18 years old) or their parents (of <18 years old). The study protocol was approved by our University Ethics Committee.

Demographic data including sex, age of diagnosis, early clinical symptoms, family history of CF and consanguinity for parents were collected. The clinical presentation of CF was classified as respiratory symptoms (purulent sputum, chronic cough, bronchiolitis, recurrent pneumonia, recurrent wheeze, atelectasis, bronchiectasis, hemoptysis, recurrent sinusitis or cor pulmonale), gastrointestinal symptoms (steatorrhea, liver disease, intestinal obstruction, diarrhea, constipation, meconium ileus or growth failure) or other symptoms (dehydration, heat exhaustion, CF-related vasculitis or diabetes mellitus).

Genomic DNA was extracted from 200 μ L of whole blood with the QiaAmp DNA Mini Kit (Qiagen, Valencia, CA, USA) and 29 common *CFTR* gene mutations (D1152H, 1717-1G>A, G542X, W1282X, N1303K, Δ F508, 3849+10kbC>T, 394delTT, 621+1G>T, S1251N, G551D, R117H, R1162X, R334W, A455E, 2183AA>G, 3659delC, 1078delT, Δ I507, R347P, R553X, E60X, 3120+1G>A, 2789+5G>A, 1898+1G>A, 711+1G>T, G85E, 2184delA and R560T) were analyzed with the ELUCIGENE CF29 v. 2 kit using four multiplex PCR. The Δ F508 mutation was further characterized as heterozygous or homozygous with this kit. Direct frequency counts and descriptive statistics were used here to report the clinical and genetic features.

Findings

Forty-five patients with CF (27 males and 18 females) from southwestern Iran were included in this study. At diagnosis our patients ranged in age from one month to 19 years; 82% of them were under 2 years old at the time of diagnosis. Their early clinical symptoms are summarized in Table 1. As shown, most patients with CF had respiratory symptoms.

Table 1: Early clinical symptoms in patients from southwestern Iran with cystic fibrosis (n=45)

Clinical symptoms	Frequency	
Respiratory symptoms	Chronic cough	38 (84%)
	Bronchiolitis	37 (82%)
	Recurrent pneumonia	35 (78%)
	Purulent sputum	34 (76%)
	Recurrent wheeze	31 (69%)
	Atelectasias	18 (40%)
	Bronchiectasis	6 (13%)
	Recurrent sinusitis	4 (9%)
	Hemoptysis	2 (4%)
	Cor pulmonale	1 (2%)
Gasterointestinal symptoms	Steatorrhea	37 (82%)
	Growth failure	24 (53%)
	Liver disease	9 (20%)
	Distal intestinal obstruction	6 (13%)
	Diarrhea	3 (7%)
	Constipation	2 (4%)
Other symptoms	Meconium ileus	2 (4%)
	Dehydration	2 (4%)
	Heat exhaustion	2 (4%)
	Vasculitis	---
	Diabetes	---

Table 2: Frequencies of *CFTR* gene mutations in a sample of patients in southwestern Iran with cystic fibrosis

CFTR gene mutations	n=45
ΔF508 (M)/ ΔF508 (M)	8 (18%)
ΔF508 (N)/ 2183AA>G	3 (7%)
ΔF508 (N)/ R1162X	2 (4%)
ΔF508 (N)/ R334W	1 (2%)
ΔF508 (N)/ N1303K	1 (2%)
ΔF508 (M)/ G542X	1 (2%)
ΔF508 (M)/ 2183AA>G	1 (2%)
ΔF508 (M)/ ΔF508 (N)	1 (2%)
Undefined	27 (60%)

Parental consanguinity was found in 40 patients (89%) and a family history of CF was reported by 15 patients (37%) in this group. A *CFTR* gene mutation was detected in 18 patients (40%). The frequencies of the mutations we detected are summarized in Table 2. Fig 1 shows the results of molecular analysis of one of the patients. The most common mutation was ΔF508, with an allele frequency of 21%. The homozygous ΔF508 mutation was observed in eight patients (18%), and three patients (7%) were ΔF508 carriers. Compound heterozygous mutations were found in two ΔF508 carriers.

Discussion

Defects in the *CFTR* gene are the main cause of CF, and molecular analysis of this gene is important for the differential diagnosis. However, the type of *CFTR* gene mutation has little effect on the age of onset and clinical presentation of the disease^[9].

The results of this study showed no correlation between the mutations we detected and the clinical presentations in our patients. Therefore, clinical signs of CF are still the best guide for diagnosing the disease, and should be taken into account by pediatricians. Our results document a 1- to 2-year delay between the first clinical presentation and the diagnosis of CF. Delayed diagnosis remains a problem which usually results in progressive disease and even irreversible changes^[10].

Cystic fibrosis, with a prevalence of 1 in 2500, is considered a common disease among Caucasians. The carrier rate of CF is reported to be about 1 in 25 among Caucasians with no family history^[11].

Because consanguinity is known to be the main cause of genetic disorders^[12], a high carrier rate implies greater risk in populations with high levels of consanguineous marriage, including some ethnic groups in Iran. The overall rate of




Fig. 1: The results of *CFTR* gene analysis with the ELUCIGENE CF29 v.2 kit. This patient was compound heterozygous for the mutant ΔF508 allele (lane A) and the 2183AA>G mutation (lanes C and D). Due to 2184delA primer cross-reactivity with the 2183AA>G mutant DNA sequence, this sample with the 2183AA>G mutation resulted in diagnostic bands of 425 bp and 169 bp in lanes C and D, respectively. A copy of the mutant ΔF508 allele (160 bp) is seen in lane A, and a copy of the normal ΔF508 allele (also 160 bp) is observed in lane B. The top and bottom bands in each lane are internal positive controls, and lane M shows the 1-kb ladder marker (http://www.gen-probe.com/pdfs/downloads/cfcf029v2_ifugb010.pdf).

consanguineous marriage among Iranians is reportedly 38.6%^[13], and ranges from 30% to 85% in different parts of the country^[14]. In our sample, 89% of the patients belonged to consanguineous families.

Unlike European countries and in agreement with other reports from Iran, the frequency of $\Delta F508$ was around 24% in our sample of patients with CF. We found no new *CFTR* gene mutations in this study, and all the mutations reported here have been previously reported in different parts of Iran^[4-8].

Although no accurate data are available regarding the prevalence of CF in different parts of Iran, the disease appears not to be rare in this country^[5]. To reduce the frequency of new cases of CF, genetic counseling before marriage and prenatal diagnosis for families with one or more affected children are necessary. Considering the high number of mutations in the *CFTR* gene and the heterogenous distribution of these mutations among different populations, determining the most common mutations in each area is necessary in order to design effective local diagnostic kits. Our results showed that a commercial kit designed to detect 29 different mutations failed to identify any *CFTR* gene mutations in 60% of our patients with CF.

Conclusion

To design an effective domestic kit, the entire *CFTR* gene should be sequenced and all *CFTR* gene rearrangements should be identified to detect prevalent and specific local mutations^[15]. Such a kit would be helpful not only for the reliable diagnosis of CF but also for premarital genetic counseling and prenatal diagnosis.

Acknowledgment

This work was supported by a grant from Shiraz University of Medical Sciences (Grant No.85-3156). We thank K. Shashok (AuthorAID in the Eastern Mediterranean) for improving the use of English in the manuscript.

Conflict of Interest: None

References

1. Moskowitz SM, Chmiel JF, Stern DL, et al. Clinical practice and genetic counseling for cystic fibrosis and CFTR-related disorders. *Genet Med* 2008; 10(12):851-68.
2. Rosenstein BJ, Cutting GR. The diagnosis of cystic fibrosis: a consensus statement. Cystic Fibrosis Foundation Consensus Panel. *J Pediatr* 1998; 132(4):589-95.
3. Cystic Fibrosis Mutation Database (CFMDB). Available at: <http://www.genet.sickkids.on.ca/cftr/StatisticsPage.html>, Access date: Sep 17, 2012.
4. Elahi E, Khodadad A, Kupersmidt I, et al. A haplotype framework for cystic fibrosis mutations in Iran. *J Mol Diagn* 2006;8(1):119-27.
5. Jalalirad M, Houshmand M, Mirfakhraie R, et al. First study of CF mutations in the *CFTR* gene of Iranian patients: detection of DeltaF508, G542X, W1282X, A120T, R117H, and R347H mutations. *J Trop Pediatr* 2004;50(6):359-61.
6. Alibakhshi R, Zamani M. Mutation analysis of *CFTR* gene in 70 Iranian cystic fibrosis patients. *Iran J Allergy Asthma Immunol* 2006;5(1):3-8.
7. Alibakhshi R, Kianishirazi R, Cassiman JJ, et al. Analysis of the *CFTR* gene in Iranian cystic fibrosis patients: identification of eight novel mutations. *J Cyst Fibros* 2008;7(2):102-9.
8. Bonyadi M, Omrani O, Rafeey M, Bilan N. Spectrum of *CFTR* gene mutations in Iranian Azeri Turkish patients with cystic fibrosis. *Genet Test Mol Biomarkers* 2011;15(1-2):89-92.
9. Vanscoy LL, Blackman SM, Collaco JM, et al. Heritability of lung disease severity in cystic fibrosis. *Am J Respir Crit Care Med* 2007;175(10):1036-43.
10. Farrell PM, Li Z, Kosorok MR, et al. Bronchopulmonary disease in children with cystic fibrosis after early or delayed diagnosis. *Am J Respir Crit Care Med* 2003;168(9):1100-8.
11. Rohlf EM, Zhou Z, Heim RA, et al. Cystic fibrosis carrier testing in an ethnically diverse US population. *Clin Chem* 2011;57(6):841-8.
12. Bittles AH, Black ML. Evolution in health and medicine Sackler colloquium: Consanguinity, human evolution, and complex diseases. *Proc Natl Acad Sci USA* 2010;107(Suppl 1):1779-86.
13. Saadat M, Ansari-Lari M, Farhud DD. Consanguineous marriage in Iran. *Ann Hum Biol* 2004;31(2):263-9.
14. Kushki AM, Zeyghami B. The effect of consanguineous marriages on congenital malformation. *J Res Med Sci* 2005;10(5):298-301.
15. Audrézet MP, Chen JM, Raguénès O, et al. Genomic rearrangements in the *CFTR* gene: extensive allelic heterogeneity and diverse mutational mechanisms. *Hum Mutat* 2004;23(4):343-57.